1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
"RFA: ACS - Discovery Cancer Interception & Prevention Program for RUNX1-FPD Hematologic Malignancies" is currently closed and not accepting applications.
RFA: ACS - Discovery Cancer Interception & Prevention Program for RUNX1-FPD Hematologic Malignancies is sponsored by American Cancer Society (ACS). This RFA aims to enable the discovery of cancer interception or prevention therapies for RUNX1-FPD hematologic malignancies.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Independent investigators at any career stage. Confirm the full requirements in the official notice before applying.
The current listing shows up to $215,000 per year direct costs for RSG award; $430,000 per year direct costs for Team award, plus 10% IDC. Awards are for up to 4 years. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was June 1, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
RFA: ACS - Discovery Cancer Interception & Prevention Program for RUNX1-FPD Hematologic Malignancies is funded by American Cancer Society (ACS). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
The Breast Cancer Research Foundation launched a $100 million venture philanthropy fund at CGI on September 22, 2026, seeded with $23 million and aiming at 20 to 30 companies. Here is what the structure actually means for investigators, for startups in the valley of death, and for every disease foundation now weighing the same move.
Read articleCDC-RFA-DP-27-0023 puts the National Breast and Cervical Cancer Early Detection Program, the National Comprehensive Cancer Control Program, and the National Program of Cancer Registries into a single competition closing February 5, 2027. Three statutorily separate eligibility pools, one application deadline, and an award count that maps onto the incumbent footprint. Here is how to read that.
Read articleCDMRP reissued the FY26 BCRP Breakthrough Award Levels 1 and 2 and the Clinical Research Extension Award on September 3, 2026, with a November 4 pre-application deadline and a November 18 full application deadline. Round one closed July 8. The arithmetic across both windows accounts for nearly the entire FY26 appropriation — which tells you what kind of second chance this is.
Read article